Page last updated: 2024-11-02

pilsicainide and Coronary Disease

pilsicainide has been researched along with Coronary Disease in 1 studies

pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sugiyama, S1
Hanaki, Y1
Ogawa, T1
Hieda, N1
Taki, K1
Ozawa, T1

Other Studies

1 other study available for pilsicainide and Coronary Disease

ArticleYear
The effects of SUN 1165, a novel sodium channel blocker, on ischemia-induced mitochondrial dysfunction and leakage of lysosomal enzymes in canine hearts.
    Biochemical and biophysical research communications, 1988, Dec-15, Volume: 157, Issue:2

    Topics: Animals; Blood Pressure; Cattle; Coronary Disease; Female; Heart; Lidocaine; Lysosomes; Male; Mitoch

1988